Thus, our results, as well as other related findings, imply that administration of GM-CSF even at a low-dose to ccRCC patients whose tumor tissues produce increased expression of GM-CSF may possibly worsen their clinical conditions. This evidence concerns the gene CSF2 and nonpapillary renal cell carcinoma.